These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25733027)

  • 41. Dose-dependent pharmacokinetics of a new Na+/H+ exchanger inhibitor KR-33028 in rats.
    Kim YH; Yoo SD; Kim YS; Lee KH; Lee HS
    Biopharm Drug Dispos; 2007 Nov; 28(8):423-9. PubMed ID: 17828714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
    Huang Z; Li H; Zhang Q; Tan X; Lu F; Liu H; Li S
    Drug Des Devel Ther; 2015; 9():4319-28. PubMed ID: 26273193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.
    Chun AW; Freshwater RE; Taft DR; Gillum AM; Maniar M
    Biopharm Drug Dispos; 2011 Mar; 32(2):99-111. PubMed ID: 21341279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans.
    Lin Z; Li M; Gehring R; Riviere JE
    J Pharm Sci; 2015 Jan; 104(1):233-43. PubMed ID: 25407474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
    Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
    Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. N- and C-terminal modifications of negamycin.
    Raju B; Mortell K; Anandan S; O'Dowd H; Gao H; Gomez M; Hackbarth C; Wu C; Wang W; Yuan Z; White R; Trias J; Patel DV
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2413-8. PubMed ID: 12824046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
    Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
    Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor.
    Jenkins S; Scola P; McPhee F; Knipe J; Gesenberg C; Sinz M; Arora V; Pilcher G; Santone K
    J Pharm Sci; 2014 Jun; 103(6):1891-902. PubMed ID: 24700293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of cefdinir levels in rat plasma and urine by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral and intravenous administration of cefdinir.
    Jin HE; Kim IB; Kim CK; Maeng HJ
    Biomed Chromatogr; 2013 Nov; 27(11):1423-30. PubMed ID: 23712418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas.
    Khier S; Gattacceca F; El Messaoudi S; Lafaille F; Deleuze-Masquéfa C; Bompart J; Cooper JF; Solassol I; Pinguet F; Bonnet PA; Bressolle FM
    Drug Metab Dispos; 2010 Oct; 38(10):1836-47. PubMed ID: 20660102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.
    Walker DK; Abel S; Comby P; Muirhead GJ; Nedderman AN; Smith DA
    Drug Metab Dispos; 2005 Apr; 33(4):587-95. PubMed ID: 15650075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats.
    Oh SJ; Lee K; Ryu J; Yu HE; Han G; Park SK; Kang JS; Kim HM; Kim YC
    Xenobiotica; 2011 Feb; 41(2):155-63. PubMed ID: 21070143
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitor.
    Cenacchi V; Battaglia R; Cinato F; Riccardi B; Spinabelli D; Brogin G; Puccini P; Pezzetta D
    Xenobiotica; 2015; 45(8):693-710. PubMed ID: 25733029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats.
    You F; Hu J; Li X; Li Y
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1453-62. PubMed ID: 23558944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor.
    Li N; Qiu Z; Wang X; Li T; Ji H; Zhang Y; Lu Y; Zhao D; Chen X
    Xenobiotica; 2014 Jan; 44(1):59-69. PubMed ID: 23773000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.